DK272986D0 - Hybridinterferoner samt deres fremstilling og anvendelse - Google Patents

Hybridinterferoner samt deres fremstilling og anvendelse

Info

Publication number
DK272986D0
DK272986D0 DK272986A DK272986A DK272986D0 DK 272986 D0 DK272986 D0 DK 272986D0 DK 272986 A DK272986 A DK 272986A DK 272986 A DK272986 A DK 272986A DK 272986 D0 DK272986 D0 DK 272986D0
Authority
DK
Denmark
Prior art keywords
interferones
hybrid
manufacturing
interferons
novel hybrid
Prior art date
Application number
DK272986A
Other languages
English (en)
Other versions
DK272986A (da
DK168794B1 (da
Inventor
Franqois Meyer
Albert Hinnen
Andreas Meister
Markus Gerhard Gruetter
Sefik Alkan
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858514726A external-priority patent/GB8514726D0/en
Priority claimed from GB858514722A external-priority patent/GB8514722D0/en
Priority claimed from GB858514724A external-priority patent/GB8514724D0/en
Priority claimed from GB858514725A external-priority patent/GB8514725D0/en
Priority claimed from GB858514723A external-priority patent/GB8514723D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of DK272986D0 publication Critical patent/DK272986D0/da
Publication of DK272986A publication Critical patent/DK272986A/da
Application granted granted Critical
Publication of DK168794B1 publication Critical patent/DK168794B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DK272986A 1985-06-11 1986-06-10 Hybridinterferonpolypeptid, fremgangsmåde til fremstilling deraf, farmaceutisk præparat med indhold deraf, hybridvektor indeholdende en DNA sekvens som koder for hybridinterferonpolypeptidet, samt vært transformeret med en ekspressionsvektor indeholdende DNA sekvensen DK168794B1 (da)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB858514726A GB8514726D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptides
GB8514722 1985-06-11
GB858514722A GB8514722D0 (en) 1985-06-11 1985-06-11 Hybrid interferon
GB8514724 1985-06-11
GB858514724A GB8514724D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon
GB8514726 1985-06-11
GB858514725A GB8514725D0 (en) 1985-06-11 1985-06-11 Hybrid polypeptide
GB8514723 1985-06-11
GB8514725 1985-06-11
GB858514723A GB8514723D0 (en) 1985-06-11 1985-06-11 Hybrid alpha-interferon

Publications (3)

Publication Number Publication Date
DK272986D0 true DK272986D0 (da) 1986-06-10
DK272986A DK272986A (da) 1986-12-12
DK168794B1 DK168794B1 (da) 1994-06-13

Family

ID=27516593

Family Applications (1)

Application Number Title Priority Date Filing Date
DK272986A DK168794B1 (da) 1985-06-11 1986-06-10 Hybridinterferonpolypeptid, fremgangsmåde til fremstilling deraf, farmaceutisk præparat med indhold deraf, hybridvektor indeholdende en DNA sekvens som koder for hybridinterferonpolypeptidet, samt vært transformeret med en ekspressionsvektor indeholdende DNA sekvensen

Country Status (20)

Country Link
US (2) US4885166A (da)
EP (1) EP0205404B1 (da)
JP (2) JPH0655759B2 (da)
KR (1) KR920002267B1 (da)
AT (1) ATE78262T1 (da)
AU (1) AU598196B2 (da)
CA (1) CA1285507C (da)
CY (1) CY1842A (da)
DE (1) DE3685996T2 (da)
DK (1) DK168794B1 (da)
FI (1) FI90983C (da)
GR (1) GR861497B (da)
HK (1) HK99895A (da)
HU (1) HU203255B (da)
IE (1) IE57865B1 (da)
IL (1) IL79085A (da)
NO (1) NO175602C (da)
NZ (1) NZ216485A (da)
PT (1) PT82736B (da)
SG (1) SG25195G (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359035A (en) * 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer
US5273889A (en) * 1990-08-22 1993-12-28 University Of Saskatchewan Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) * 1990-08-22 1997-01-14 University Of Saskatchewan Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
US5372808A (en) † 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
ATE157703T1 (de) * 1991-12-16 1997-09-15 Ciba Geigy Ag Endoplasmatisches retikulum-ständige rekombinante dibasische endoprotease und deren verwendungen
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
EP0584343B1 (en) * 1992-03-10 1999-01-20 La Jolla Cancer Research Foundation Recombinant calf intestinal alkaline phosphatase
TW218846B (da) * 1992-04-07 1994-01-11 Ciba Geigy
JPH078215A (ja) * 1993-04-30 1995-01-13 Kawasaki Steel Corp ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法
TW249202B (da) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
ATE207538T1 (de) 1995-02-09 2001-11-15 Behringwerke Ag Verfahren zur produktion von proteinen
TW442492B (en) * 1995-07-26 2001-06-23 Novartis Ag Process for the enrichment of interferon
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
NZ540043A (en) * 2002-11-18 2007-11-30 Maxygen Inc Isolated or recombinant Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2005113592A2 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2006004959A2 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CA2607651A1 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
FI2343362T4 (fi) 2006-07-14 2024-07-04 Patheon Holdings I B V Parannettu menetelmä solujen viljelyä varten
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
WO2008070135A2 (en) 2006-12-06 2008-06-12 Medimmune, Llc. Methods of treating systemic lupus erythematosus
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
CN101675071B (zh) * 2007-05-02 2014-06-18 Ambrx公司 经修饰干扰素β多肽和其用途
WO2008137838A2 (en) 2007-05-03 2008-11-13 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
WO2009100342A2 (en) 2008-02-08 2009-08-13 Medimmune, Llc Disease markers and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CA2846786C (en) 2011-03-15 2022-05-17 Biogen Idec Inc. Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
US8729236B2 (en) * 2011-05-23 2014-05-20 Hal S. Padgett Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
EP3924383A1 (en) 2019-02-15 2021-12-22 Astrazeneca AB Type i interferon-mediated disorders
WO2021203013A2 (en) 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
KR102594862B1 (ko) * 2023-06-14 2023-10-27 (주) 신성하이스킬 화재방지 파쇄 시스템
KR102570958B1 (ko) * 2023-06-14 2023-08-25 (주) 신성하이스킬 화재방지 4축 파쇄장치

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE54096B1 (en) * 1980-01-08 1989-06-21 Biogen Nv Dn sequences, recombinant dna molecules and processes for producing human interferon - like polypeptides
US4456748A (en) * 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
ES8302778A1 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) * 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof
WO1983002461A1 (en) * 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
GB8317880D0 (en) * 1983-07-01 1983-08-03 Searle & Co Structure and synthesis of interferons
EP0146903A3 (en) * 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
EP0173935A1 (en) * 1984-08-31 1986-03-12 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
US4716217A (en) * 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons

Also Published As

Publication number Publication date
IL79085A (en) 1992-03-29
JPH0736757B2 (ja) 1995-04-26
US5071761A (en) 1991-12-10
HU203255B (en) 1991-06-28
DK272986A (da) 1986-12-12
DK168794B1 (da) 1994-06-13
DE3685996D1 (de) 1992-08-20
DE3685996T2 (de) 1993-01-14
SG25195G (en) 1995-08-18
NZ216485A (en) 1991-06-25
EP0205404A3 (en) 1987-10-21
IL79085A0 (en) 1986-09-30
IE57865B1 (en) 1993-05-05
AU5849986A (en) 1986-12-18
AU598196B2 (en) 1990-06-21
HK99895A (en) 1995-06-30
NO862313L (no) 1986-12-12
JPH05308973A (ja) 1993-11-22
NO175602C (no) 1994-11-02
PT82736A (en) 1986-07-01
JPH0655759B2 (ja) 1994-07-27
GR861497B (en) 1986-10-10
IE861542L (en) 1986-12-11
PT82736B (pt) 1988-12-15
KR870000427A (ko) 1987-02-18
US4885166A (en) 1989-12-05
FI90983C (fi) 1994-04-25
EP0205404A2 (en) 1986-12-17
ATE78262T1 (de) 1992-08-15
CA1285507C (en) 1991-07-02
JPS626000A (ja) 1987-01-12
NO862313D0 (no) 1986-06-10
HUT41846A (en) 1987-05-28
FI90983B (fi) 1994-01-14
EP0205404B1 (en) 1992-07-15
FI862461L (fi) 1986-12-12
FI862461A0 (fi) 1986-06-09
NO175602B (no) 1994-07-25
KR920002267B1 (ko) 1992-03-20
CY1842A (en) 1996-03-08

Similar Documents

Publication Publication Date Title
DK272986A (da) Hybridinterferoner samt deres fremstilling og anvendelse
DE3583521D1 (de) Antivirale verbindungen.
ATE113603T1 (de) Antivirale nukleoside.
FI874287A7 (fi) Uudet lymfokiinipeptidit.
FI863378A0 (fi) Rengoeringsfoerfarande av interferon.
IT8124967A0 (it) Interferoni di leucociti umani ibridi.
FI850275L (fi) Nya 6-susbtituerade furo-(3,4-c) -pyridinderivat.
FI872808L (fi) Nya topiskt applicerbara farmaceutiska sammansaettningar med systemisk verkan.
FI870377L (fi) Antivirala kompositioner.
DE69000743D1 (de) Antivirale tetrahydroimidazo(1,4)benzodiazepin-2-thione.
FI873593L (fi) Nya applikationsformer foer -interferon.
FI872096A0 (fi) Foerhoejd expression av humant interleukin-2 i daeggdjursceller.
FI891279L (fi) Antivirala tetrahydroimidazol /1,4/ benzodiazepin-2-oner.
EP0315637A4 (en) POLYPEPTIDES USEFUL IN THE DIAGNOSIS OF MYCOPLASMA INFECTIONS IN PIGS, AND RECOMBINANT DNA METHODS FOR THEIR MANUFACTURE.
DE3577713D1 (de) Thermoplastische, weichmacherhaltige polyvinylbutyralformmassen.
DE3575435D1 (de) Sinterfaehige, feinteilige formmasse auf basis von vinylchlorid-polymerisaten.
NO861635L (no) Fremgangsmaate for fremstilling av rekombinert aaa-interferon.
FI860614A7 (fi) Foenster, doerr respektive fast isatt glas med skjutsaeker skiva.
FI863405L (fi) Nya bbm-1675c- och d-antibiotika med antitumoereffekt.
FI930024A0 (fi) Nya antivirala tetrahydroimidazo(1,4)benzodiazepin-2-(ti)oner
NO894573D0 (no) Rekombinante interleukin-2 hybridproteiner.
FI865128A0 (fi) Nya 16,17-acetalsubstituerade pregnan-21-karboxylsyraderivat.
FI864751A0 (fi) Nya 2,2'-bi-1h-imidazoler.
ATA551881A (de) Dreilagiger formkoerper, insbesondere blech, von hoher verschleissfestigkeit
DE3673139D1 (de) Sinterfaehige, feinteilige formmasse auf basis von vinylchlorid-polymerisaten.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired